Dentistry of patients receiving intravenous anticoagulants
Anticoagulants and antiplatelet drugs are drugs that reduce the possibility of blood clots in the arteries, veins, or heart. Clots can block blood flow in your heart muscle and result in a heart attack. They can also block blood flow to your brain and lead to a stroke.
Low molecular weight heparin (LMWHs), dalteparin (Fragmin), enoxaparin (Clexan), and tinzaparin (innoheb) have been discussed more subcutaneously than orally. Although it is used in a limited group of patients, there is a possibility of exposure in the dental office.
Patients taking low molecular weight heparin (LMWHs), including pregnant women with recommended (mandatory) use of anticoagulants and patients with venous thrombosis with a history of cancer. These drugs may be used once or twice a day, both prophylactically and therapeutically. Like new anticoagulants, these drugs have a rapid onset of action and a short half-life.
What is the treatment?
There is a lack of clinical evidence for patients using intravenous anticoagulants (LMWHs). In addition, patients receiving these drugs may have different medical conditions and drug regimens. In this case, additional information is needed to make a rational decision about treatment management. In this case, the patient’s doctor should be consulted. For dialysis patients who are prescribed heparin or LMWHs, although it has a short half-life, there is a possibility of bleeding, and it is better to postpone dental procedures until the next day.
